Literature DB >> 2704542

Optic nerve involvement in retinoblastoma.

I Magramm1, D H Abramson, R M Ellsworth.   

Abstract

This retrospective review of 814 retinoblastoma patients discloses 240 cases of tumor extension into the optic nerve. Optic nerve involvement was classified according to the degree of invasion; grade I is superficial invasion of the optic nerve head only, grade II is involvement up to and including the lamina cribrosa, grade III is involvement beyond the lamina cribrosa, and grade IV is involvement up to and including the surgical margin. The incidence of optic nerve involvement was 29.5% (240/814). The mortality rate of patients with optic nerve involvement with grade I was 10%; grade II, 29%; grade III, 42%; and grade IV, 78%. Actuarial life-table analysis shows an increased mortality rate with increasing grade of optic nerve involvement. Multivariate statistical analysis shows that the grade of optic nerve involvement and the age at diagnosis of optic nerve involvement are the factors most significantly associated with survival.

Entities:  

Mesh:

Year:  1989        PMID: 2704542     DOI: 10.1016/s0161-6420(89)32910-1

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  21 in total

Review 1.  Chemotherapy for retinoblastoma: a current topic.

Authors:  P T Finger; G Czechonska; H Demirci; A Rausen
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

2.  Comparison of high-risk histopathological features in eyes with primary or secondary enucleation for retinoblastoma.

Authors:  Rachel C Brennan; Ibrahim Qaddoumi; Catherine A Billups; Tammy L Free; Barrett G Haik; Carlos Rodriguez-Galindo; Matthew W Wilson
Journal:  Br J Ophthalmol       Date:  2015-04-14       Impact factor: 4.638

3.  Retinoblastoma. Fifty years of progress. The LXXI Edward Jackson Memorial Lecture.

Authors:  Hans E Grossniklaus
Journal:  Am J Ophthalmol       Date:  2014-07-24       Impact factor: 5.258

4.  Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy: A Children's Oncology Group Study.

Authors:  Patricia Chévez-Barrios; Ralph C Eagle; Mark Krailo; Jin Piao; Daniel M Albert; Yun Gao; Geeta Vemuganti; Mohammad Javed Ali; Vikas Khetan; Santosh G Honavar; Joan O'Brien; Ann-Marie Leahey; Katherine Matthay; Anna Meadows; Murali Chintagumpala
Journal:  J Clin Oncol       Date:  2019-09-20       Impact factor: 44.544

5.  Retinoblastoma associated orbital cellulitis.

Authors:  P B Mullaney; Z A Karcioglu; A M Huaman; S al-Mesfer
Journal:  Br J Ophthalmol       Date:  1998-05       Impact factor: 4.638

6.  Relevance of CT and MRI in retinoblastoma for the diagnosis of postlaminar invasion with normal-size optic nerve: a retrospective study of 150 patients with histological comparison.

Authors:  Hervé J Brisse; Myriam Guesmi; Isabelle Aerts; Xavier Sastre-Garau; Alexia Savignoni; Livia Lumbroso-Le Rouic; Laurence Desjardins; François Doz; Bernard Asselain; Danièle Bours; Sylvia Neuenschwander
Journal:  Pediatr Radiol       Date:  2007-05-04

7.  Diagnostic performance of MRI of post-laminar optic nerve invasion detection in retinoblastoma: A systematic review and meta-analysis.

Authors:  Se Jin Cho; Jae Hyoung Kim; Sung Hyun Baik; Leonard Sunwoo; Yun Jung Bae; Byung Se Choi
Journal:  Neuroradiology       Date:  2020-08-31       Impact factor: 2.804

8.  Retinoblastoma patients with high risk ocular pathological features: who needs adjuvant therapy?

Authors:  G L Chantada; I J Dunkel; M T G de Dávila; D H Abramson
Journal:  Br J Ophthalmol       Date:  2004-08       Impact factor: 4.638

9.  Choroidal invasion of retinoblastoma: metastatic potential and clinical risk factors.

Authors:  C L Shields; J A Shields; K A Baez; J Cater; P V De Potter
Journal:  Br J Ophthalmol       Date:  1993-09       Impact factor: 4.638

10.  Tumour angiogenesis as a prognostic factor for disease dissemination in retinoblastoma.

Authors:  E Ferrari Marback; V E A Arias; A Paranhos; F A Soares; A L Murphree; C M Erwenne
Journal:  Br J Ophthalmol       Date:  2003-10       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.